Is Dyne TherapeuticsInc Stock a Good Investment?
Dyne TherapeuticsInc Investment Advice | DYN |
- Examine Dyne TherapeuticsInc's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Dyne TherapeuticsInc's leadership team and their track record. Good management can help Dyne TherapeuticsInc navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Dyne TherapeuticsInc's business and its evolving consumer preferences.
- Compare Dyne TherapeuticsInc's performance and market position to its competitors. Analyze how Dyne TherapeuticsInc is positioned in terms of product offerings, innovation, and market share.
- Check if Dyne TherapeuticsInc pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Dyne TherapeuticsInc's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Dyne TherapeuticsInc stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Dyne TherapeuticsInc is a good investment.
Sell | Buy |
Sell
Market Performance | Modest | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Dyne TherapeuticsInc Stock
Researching Dyne TherapeuticsInc's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 89.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings To Growth (PEG) ratio of 0.19. Dyne TherapeuticsInc recorded a loss per share of 3.98. The entity last dividend was issued on the May 30, 2002. The firm had 1:5 split on the May 25, 2010.
To determine if Dyne TherapeuticsInc is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Dyne TherapeuticsInc's research are outlined below:
| Dyne TherapeuticsInc had very high historical volatility over the last 90 days | |
| Reported Net Loss for the year was (235.94 M) with profit before taxes, overhead, and interest of 0. | |
| Dyne TherapeuticsInc has about 291.84 M in cash with (188.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.64. | |
| Over 89.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from investorplace.com: DYN Stock Earnings Dyne Therapeutics Misses EPS for Q1 2024 |
Dyne TherapeuticsInc Quarterly Good Will |
|
Dyne TherapeuticsInc uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Dyne TherapeuticsInc. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Dyne TherapeuticsInc's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 7th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 7th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Dyne TherapeuticsInc's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Dyne TherapeuticsInc's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2017-12-31 | 2017-12-31 | -0.42 | -0.35 | 0.07 | 16 | ||
2023-03-02 | 2022-12-31 | -0.84 | -0.74 | 0.1 | 11 | ||
2021-05-06 | 2021-03-31 | -0.6 | -0.5 | 0.1 | 16 | ||
2022-11-03 | 2022-09-30 | -0.92 | -0.8 | 0.12 | 13 | ||
2023-10-30 | 2023-09-30 | -0.83 | -0.99 | -0.16 | 19 | ||
2024-02-08 | 2023-12-31 | -0.92 | -1.09 | -0.17 | 18 | ||
2022-05-02 | 2022-03-31 | -0.88 | -0.69 | 0.19 | 21 | ||
2021-11-04 | 2021-09-30 | -0.64 | -0.83 | -0.19 | 29 |
Dyne TherapeuticsInc Target Price Consensus
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Dyne target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Dyne TherapeuticsInc's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 10 | Strong Buy |
Most Dyne analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Dyne stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Dyne TherapeuticsInc, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationDyne TherapeuticsInc Target Price Projection
Dyne TherapeuticsInc's current and average target prices are 25.69 and 29.50, respectively. The current price of Dyne TherapeuticsInc is the price at which Dyne TherapeuticsInc is currently trading. On the other hand, Dyne TherapeuticsInc's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Dyne TherapeuticsInc Market Quote on 9th of May 2024
Target Price
Analyst Consensus On Dyne TherapeuticsInc Target Price
Dyne TherapeuticsInc Analyst Ratings
Dyne TherapeuticsInc's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Dyne TherapeuticsInc stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Dyne TherapeuticsInc's financials, market performance, and future outlook by experienced professionals. Dyne TherapeuticsInc's historical ratings below, therefore, can serve as a valuable tool for investors.Know Dyne TherapeuticsInc's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Dyne TherapeuticsInc is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Dyne TherapeuticsInc backward and forwards among themselves. Dyne TherapeuticsInc's institutional investor refers to the entity that pools money to purchase Dyne TherapeuticsInc's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Wasatch Advisors Lp | 2023-12-31 | 1.7 M | Tcg Crossover Management, Llc | 2023-12-31 | 1.7 M | Nantahala Capital Management, Llc | 2023-12-31 | 1.3 M | Fmr Inc | 2023-12-31 | 1.3 M | Artal Group S A | 2023-12-31 | 1.2 M | Vivo Capital, Llc | 2023-12-31 | 1 M | Sofinnova Ventures | 2023-12-31 | 1 M | Geode Capital Management, Llc | 2023-12-31 | 932.8 K | Commodore Capital Lp | 2023-12-31 | 900 K | Fcpm Iii Services Bv | 2023-12-31 | 6.1 M | Mpm Asset Management, Llc | 2023-12-31 | 5 M |
Dyne TherapeuticsInc's market capitalization trends
The company currently falls under 'Mid-Cap' category with a total capitalization of 2.24 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Dyne TherapeuticsInc's market, we take the total number of its shares issued and multiply it by Dyne TherapeuticsInc's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Market Cap |
|
Dyne TherapeuticsInc's profitablity analysis
Dyne TherapeuticsInc's profitability indicators refer to fundamental financial ratios that showcase Dyne TherapeuticsInc's ability to generate income relative to its revenue or operating costs. If, let's say, Dyne TherapeuticsInc is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Dyne TherapeuticsInc's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Dyne TherapeuticsInc's profitability requires more research than a typical breakdown of Dyne TherapeuticsInc's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.43) | (1.36) | |
| Return On Capital Employed | (2.12) | (2.02) | |
| Return On Assets | (1.43) | (1.36) | |
| Return On Equity | (2.58) | (2.46) |
Determining Dyne TherapeuticsInc's profitability involves analyzing its financial statements and using various financial metrics to determine if Dyne TherapeuticsInc is a good buy. For example, gross profit margin measures Dyne TherapeuticsInc's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Dyne TherapeuticsInc's profitability and make more informed investment decisions.
The data published in Dyne TherapeuticsInc's official financial statements usually reflect Dyne TherapeuticsInc's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Dyne TherapeuticsInc. For example, before you start analyzing numbers published by Dyne accountants, it's critical to develop an understanding of what Dyne TherapeuticsInc's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Dyne TherapeuticsInc's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Dyne TherapeuticsInc's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Dyne TherapeuticsInc's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Dyne TherapeuticsInc. Please utilize our Beneish M Score to check the likelihood of Dyne TherapeuticsInc's management manipulating its earnings.
Evaluate Dyne TherapeuticsInc's management efficiency
Dyne TherapeuticsInc has Return on Asset of (0.4098) % which means that on every $100 spent on assets, it lost $0.4098. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.715) %, meaning that it generated no profit with money invested by stockholders. Dyne TherapeuticsInc's management efficiency ratios could be used to measure how well Dyne TherapeuticsInc manages its routine affairs as well as how well it operates its assets and liabilities. As of the 9th of May 2024, Return On Tangible Assets is likely to grow to -1.36. In addition to that, Return On Capital Employed is likely to grow to -2.02. As of the 9th of May 2024, Debt To Assets is likely to grow to 0.26, while Total Assets are likely to drop about 156.8 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.53 | 1.45 | |
| Net Current Asset Value | 0.00 | 0.00 | |
| Tangible Asset Value | 0.00 | 0.00 | |
| Tangible Book Value Per Share | 1.53 | 1.45 | |
| Enterprise Value Over EBITDA | (2.92) | (2.77) | |
| Price Book Value Ratio | 8.70 | 9.13 | |
| Enterprise Value Multiple | (2.92) | (2.77) | |
| Price Fair Value | 8.70 | 9.13 | |
| Enterprise Value | 699.6 M | 465.6 M |
The analysis of Dyne TherapeuticsInc's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Dyne TherapeuticsInc's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Dyne Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta 0.952 |
Basic technical analysis of Dyne Stock
As of the 9th of May, Dyne TherapeuticsInc shows the Coefficient Of Variation of 1025.94, mean deviation of 3.07, and Downside Deviation of 3.93. Dyne TherapeuticsInc technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We have analyzed and interpolated nineteen technical drivers for Dyne TherapeuticsInc, which can be compared to its peers. Please confirm Dyne TherapeuticsInc coefficient of variation, treynor ratio, as well as the relationship between the Treynor Ratio and semi variance to decide if Dyne TherapeuticsInc is priced favorably, providing market reflects its regular price of 25.69 per share. Given that Dyne TherapeuticsInc has jensen alpha of 0.3251, we urge you to verify Dyne TherapeuticsInc's prevailing market performance to make sure the company can sustain itself at a future point.Dyne TherapeuticsInc's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Dyne TherapeuticsInc insiders, such as employees or executives, is commonly permitted as long as it does not rely on Dyne TherapeuticsInc's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Dyne TherapeuticsInc insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Understand Dyne TherapeuticsInc's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Dyne TherapeuticsInc's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0687 | |||
| Market Risk Adjusted Performance | 0.7573 | |||
| Mean Deviation | 3.07 | |||
| Semi Deviation | 3.68 | |||
| Downside Deviation | 3.93 | |||
| Coefficient Of Variation | 1025.94 | |||
| Standard Deviation | 3.82 | |||
| Variance | 14.63 | |||
| Information Ratio | 0.0745 | |||
| Jensen Alpha | 0.3251 | |||
| Total Risk Alpha | (0.12) | |||
| Sortino Ratio | 0.0726 | |||
| Treynor Ratio | 0.7473 | |||
| Maximum Drawdown | 16.32 | |||
| Value At Risk | (6.11) | |||
| Potential Upside | 6.07 | |||
| Downside Variance | 15.41 | |||
| Semi Variance | 13.54 | |||
| Expected Short fall | (3.19) | |||
| Skewness | (0.17) | |||
| Kurtosis | (0.49) |
| Risk Adjusted Performance | 0.0687 | |||
| Market Risk Adjusted Performance | 0.7573 | |||
| Mean Deviation | 3.07 | |||
| Semi Deviation | 3.68 | |||
| Downside Deviation | 3.93 | |||
| Coefficient Of Variation | 1025.94 | |||
| Standard Deviation | 3.82 | |||
| Variance | 14.63 | |||
| Information Ratio | 0.0745 | |||
| Jensen Alpha | 0.3251 | |||
| Total Risk Alpha | (0.12) | |||
| Sortino Ratio | 0.0726 | |||
| Treynor Ratio | 0.7473 | |||
| Maximum Drawdown | 16.32 | |||
| Value At Risk | (6.11) | |||
| Potential Upside | 6.07 | |||
| Downside Variance | 15.41 | |||
| Semi Variance | 13.54 | |||
| Expected Short fall | (3.19) | |||
| Skewness | (0.17) | |||
| Kurtosis | (0.49) |
Consider Dyne TherapeuticsInc's intraday indicators
Dyne TherapeuticsInc intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Dyne TherapeuticsInc stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Daily Balance Of Power | 9.2 T | |||
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 25.69 | |||
| Day Typical Price | 25.69 | |||
| Price Action Indicator | 0.02 | |||
| Period Momentum Indicator | 0.04 |
Dyne TherapeuticsInc Corporate Filings
10Q | 2nd of May 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
| 5th of April 2024 Other Reports | ViewVerify | |
13A | 4th of April 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
F3 | 27th of March 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Dyne Stock media impact
Far too much social signal, news, headlines, and media speculation about Dyne TherapeuticsInc that are available to investors today. That information is available publicly through Dyne media outlets and privately through word of mouth or via Dyne internal channels. However, regardless of the origin, that massive amount of Dyne data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Dyne TherapeuticsInc news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Dyne TherapeuticsInc relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Dyne TherapeuticsInc's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Dyne TherapeuticsInc alpha.
Dyne TherapeuticsInc Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Dyne TherapeuticsInc can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Dyne TherapeuticsInc Historical Investor Sentiment
Investor biases related to Dyne TherapeuticsInc's public news can be used to forecast risks associated with an investment in Dyne. The trend in average sentiment can be used to explain how an investor holding Dyne can time the market purely based on public headlines and social activities around Dyne TherapeuticsInc. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Dyne TherapeuticsInc's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Dyne TherapeuticsInc and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Dyne TherapeuticsInc news discussions. The higher the estimate score, the more favorable the investor's outlook on Dyne TherapeuticsInc.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Dyne TherapeuticsInc without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Diagnostics Now
Portfolio DiagnosticsUse generated alerts and portfolio events aggregator to diagnose current holdings |
| All Next | Launch Module |
Dyne TherapeuticsInc Corporate Management
Elected by the shareholders, the Dyne TherapeuticsInc's board of directors comprises two types of representatives: Dyne TherapeuticsInc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Dyne. The board's role is to monitor Dyne TherapeuticsInc's management team and ensure that shareholders' interests are well served. Dyne TherapeuticsInc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Dyne TherapeuticsInc's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Romesh Subramanian | CoFounder Advisor | Profile | |
| Richard MBA | Senior Administration | Profile | |
| Oxana Beskrovnaya | Chief Officer | Profile | |
| Daniel Wilson | Senior Legal | Profile | |
| Susanna MBA | Chief Officer | Profile | |
| MS MD | VP Pharmacovigilance | Profile |
How to buy Dyne Stock?
To provide specific investment advice or recommendations on Dyne TherapeuticsInc stock, we recommend investors consider the following general factors when evaluating Dyne TherapeuticsInc. This will help you to make an informed decision on whether to include Dyne TherapeuticsInc in one of your diversified portfolios:- Examine Dyne TherapeuticsInc's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Dyne TherapeuticsInc's leadership team and their track record. Good management can help Dyne TherapeuticsInc navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Dyne TherapeuticsInc's business and its evolving consumer preferences.
- Compare Dyne TherapeuticsInc's performance and market position to its competitors. Analyze how Dyne TherapeuticsInc is positioned in terms of product offerings, innovation, and market share.
- Check if Dyne TherapeuticsInc pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Dyne TherapeuticsInc's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Dyne TherapeuticsInc stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Dyne TherapeuticsInc is a good investment.
Already Invested in Dyne TherapeuticsInc?
The danger of trading Dyne TherapeuticsInc is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Dyne TherapeuticsInc is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Dyne TherapeuticsInc. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Dyne TherapeuticsInc is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Dyne TherapeuticsInc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dyne TherapeuticsInc's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dyne Therapeuticsinc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dyne Therapeuticsinc Stock: Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dyne TherapeuticsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing. To learn how to invest in Dyne Stock, please use our How to Invest in Dyne TherapeuticsInc guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Complementary Tools for Dyne Stock analysis
When running Dyne TherapeuticsInc's price analysis, check to measure Dyne TherapeuticsInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dyne TherapeuticsInc is operating at the current time. Most of Dyne TherapeuticsInc's value examination focuses on studying past and present price action to predict the probability of Dyne TherapeuticsInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dyne TherapeuticsInc's price. Additionally, you may evaluate how the addition of Dyne TherapeuticsInc to your portfolios can decrease your overall portfolio volatility.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |
Is Dyne TherapeuticsInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dyne TherapeuticsInc. If investors know Dyne will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dyne TherapeuticsInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.98) | Return On Assets (0.41) | Return On Equity (0.71) |
The market value of Dyne TherapeuticsInc is measured differently than its book value, which is the value of Dyne that is recorded on the company's balance sheet. Investors also form their own opinion of Dyne TherapeuticsInc's value that differs from its market value or its book value, called intrinsic value, which is Dyne TherapeuticsInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dyne TherapeuticsInc's market value can be influenced by many factors that don't directly affect Dyne TherapeuticsInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Dyne TherapeuticsInc's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Dyne TherapeuticsInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dyne TherapeuticsInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.